Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.
Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin CT. Gelfand JM, et al. Among authors: ritchlin ct. J Am Acad Dermatol. 2020 Dec;83(6):1704-1716. doi: 10.1016/j.jaad.2020.09.001. Epub 2020 Sep 4. J Am Acad Dermatol. 2020. PMID: 32891785 Free PMC article.
Outcome measures in psoriatic arthritis.
Gladman DD, Mease PJ, Krueger G, van der Heidje DM, Antoni C, Helliwell PS, Kavanaugh AF, Nash P, Ritchlin CT, Strand CV, Taylor W. Gladman DD, et al. Among authors: ritchlin ct. J Rheumatol. 2005 Nov;32(11):2262-9. J Rheumatol. 2005. PMID: 16265714
National Psoriasis Foundation clinical consensus on disease severity.
Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, Van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, Horn EJ; National Psoriasis Foundation. Pariser DM, et al. Among authors: ritchlin ct. Arch Dermatol. 2007 Feb;143(2):239-42. doi: 10.1001/archderm.143.2.239. Arch Dermatol. 2007. PMID: 17310004
Composite measures in psoriatic arthritis: GRAPPA 2008.
Gladman DD, Landewé R, McHugh NJ, Fitzgerald O, Thaci D, Coates L, Mease PJ, Qureshi AA, Krueger GG, Ritchlin CT, Kavanaugh AF, Garg A. Gladman DD, et al. Among authors: ritchlin ct. J Rheumatol. 2010 Feb;37(2):453-61. doi: 10.3899/jrheum.090956. J Rheumatol. 2010. PMID: 20147481
Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008.
Ritchlin CT, Qureshi AA, de Vlam K, Pitzalis C, Helliwell PS, Mease PJ, Gladman DD, Krueger GG, Kavanaugh AF, Fitzgerald O. Ritchlin CT, et al. J Rheumatol. 2010 Feb;37(2):462-7. doi: 10.3899/jrheum.090957. J Rheumatol. 2010. PMID: 20147482
Consensus guidelines for the management of plaque psoriasis.
Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr; National Psoriasis Foundation Medical Board. Hsu S, et al. Among authors: ritchlin ct. Arch Dermatol. 2012 Jan;148(1):95-102. doi: 10.1001/archdermatol.2011.1410. Arch Dermatol. 2012. PMID: 22250239
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.
Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT. Coates LC, et al. Among authors: ritchlin ct. Arthritis Rheumatol. 2016 May;68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23. Arthritis Rheumatol. 2016. PMID: 26749174
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group. Mease PJ, et al. Among authors: ritchlin ct. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23. Ann Rheum Dis. 2017. PMID: 27553214 Free PMC article. Clinical Trial.
246 results